药学英语专业课PPT(绝对原创：免费附赠翻译请自行下载).pptxVIP

Angiogenesis inhibitor enters clinical trials zuozhe Vascular system of the human bodyNew wordsangiogenesis血管生成inhibitor拮抗剂clinical临床的vessel血管的isocoumarin香豆素endostatin内皮抑素tumour 肿瘤efficancy 疗效评估psoriasis牛皮癣New wordsdosage药剂；药量cytotoxic细胞毒素vessel血管的concomitant相伴的；共存的ionizing电离regression复原umbilical脐带collaborator共同研究者rheumatoid风湿病 A new orally active angiogenesis inhibitor for cancer treatment, has entered clinical trials in France. The inhibitor appears to work by blocking a critical factor in the mediation of new blood vessel growth, vascular endothelial growth factor (VEGF). The compound, an isocoumarin derivative, suppresses the hypoxia-induced VEGF activity at the mRNA and protein level. The aim of the design of anti-angiogenesis compounds is to eliminate the supply of nutrients via the blood to the tumour cells. Other research into angio-genesis inhibition has focused on proteins such as angiostatin and endostatin French connection Patrick Soulie and his colleagues at Centre Paul Papin have already initiated patient screening for enrolment into the Phase clinical trial of NM-3, which will reveal its side-effect profile, efficancy and dosage tolerance. The drug will be used as a standalone treatment for all types of cancers. ILEX recently announced results from its preclinical studies to the American Association for Cancer Research 91st Annual Meeting . Two preclinical animal studies of NM-3 demonstrated the oral activity of the com-pound. Agata and his team reported that NM-3 inhibited tumour growth by 80% compared with the control group. Previously, Agata had reported the process of angiogenesis inhibition by NM-3.Weichselbaum and his colleagues at the Dana Farber Cancer Center and University of Chicago also offered data on NM-3 demonstrating its ability to block the growth of endothelial cells that ultimately lead to new blood vessel formation of tumours. Indeed, in vitro NM-3 is selectively cytotoxic to endothelial cells.Radiation combination Wechsel